Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Genetically modified natural killer cells for CD70-directed cancer immunotherapy

Genetically modified natural killer cells for CD70-directed cancer immunotherapy

US Patent 12012458 · Granted Jun 18, 2024

Estimated economic value: $16,214,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Immune cells comprising truncated NKG2D chimeric receptors2025
Gene expression markers for predicting overall survival in subjects treated with2024
Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of2023
Methods of using interleukin-10 for treating diseases and disorders2022
Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immun2022
Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immun2022